Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy
Authors:
- Dennis L. CitrinDCDennis L. Citrin
- Bradford A. TanBTBradford A. Tan
- Nimesh B. PatelNPNimesh B. Patel
- Vicki DoctorVDVicki Doctor
- Siraj M. AliSASiraj M. Ali
- Ankur R. ParikhAPAnkur R. Parikh
- Maurie MarkmanMMMaurie Markman
- Jeffrey S. RossJRJeffrey S. Ross
- Arun Kadamkulam SyriacASArun Kadamkulam Syriac
- Sara J. BrzezinskiSBSara J. Brzezinski
- 1 November 2018
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 2 (2) , 1-7
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- HER2 Activating Mutations in Estrogen Receptor Positive Breast CancerCurrent Breast Cancer Reports, 2018
- HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase InhibitorJournal of the National Comprehensive Cancer Network, 2015
- Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F MutationJournal of the National Comprehensive Cancer Network, 2015
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical TrialsJournal of Clinical Oncology, 2015
- Cancer Signature Investigation:ERBB2(HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung PrimaryJournal of the National Comprehensive Cancer Network, 2015
- Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted TherapyJournal of Clinical Oncology, 2014
- Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency ofHER2(ERBB2) Gene MutationsClinical Cancer Research, 2013
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast CancerCancer Discovery, 2013
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005